Treatment of intestinal fibrosis of Crohn disease by regulation of expression of glycan chains

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590938
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Niigata University
• Principal Investigator: SUZUKI Kenji 新潟大学, 医歯学総合病院, 講師 (00303123)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: siRNA / 線維化 / 糖鎖 / クローン病 / 消化管狭窄

Outline of Final Research Achievements

We have revealed that the carbohydrate sulphotransferase CHST15 gene plays an important role in intestinal fibrosis in Crohn's disease, and developed a siRNA drug, STNM01, which selectively inhibits the expression of the gene, collaborating with the Stelic Institute of Regenerative Medicine, Tokyo.
In this study, we have revealed that this new siRNA drug inhibited the progression of fibroblasts into myofibroblasts, and decresed the collagen production by fibroblasts, and that STNM01 could ameliorate chronic fibrosing DSS colitis. Additionally, we have revealed the overexpression of CHST15 in the colon of patients with Crohn's diseasae, suggesting that CHS15 could be a promissing target of the siRNA drug for the treatment of intestinal fibrosis in Crohn's disease.

Free Research Field

消化器内科学